Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.
The European Commission approved Tecentriq, also known as atezolizumab, as a monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) after patients have been treated with chemotherapy.
{iframe}http://whtc.com/news/articles/2017/sep/23/roche-cancer-immunotherapy-tecentriq-wins-eu-approval/{/iframe}